HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985–2015

Abstract Background HIV-positive people who use drugs (PWUD) start antiretroviral therapy (ART) later than other risk groups, and among HCV-positive PWUD, HCV treatment uptake is low. Nowadays, HCV direct-acting antivirals (DAAs) are available and reimbursed in the Netherlands (since 2014). The Amst...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The International journal of drug policy 2017-09, Vol.47, p.95-101
Hauptverfasser:	van Santen, Daniëla K, van der Helm, Jannie J, Lindenburg, Karen, Schim van der Loeff, Maarten, Prins, Maria
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiretroviral drugs Antiretroviral therapy Antiviral drugs Cohort analysis Competing risks models DAA Data analysis Drug policy Drug therapy Drug use Drug Users - psychology Drug Users - statistics & numerical data Drugs Female HCV Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C - epidemiology Hepatitis C - psychology HIV HIV Infections - drug therapy HIV Infections - epidemiology HIV Infections - psychology Human immunodeficiency virus Humans Internal Medicine Male Medical Education Medical records Mortality Netherlands - epidemiology Patient Acceptance of Health Care - statistics & numerical data People who use drugs (PWUD) Questionnaires Risk Treatment Uptake
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Background HIV-positive people who use drugs (PWUD) start antiretroviral therapy (ART) later than other risk groups, and among HCV-positive PWUD, HCV treatment uptake is low. Nowadays, HCV direct-acting antivirals (DAAs) are available and reimbursed in the Netherlands (since 2014). The Amsterdam Cohort Studies (ACS), initiated in 1985, provides us the opportunity to describe temporal trends in ART and HCV-treatment uptake among PWUD through 2015. Methods We analyzed data from PWUD participating in the ACS between 1985 and 2015. ART and HCV-treatment data were obtained from ACS questionnaires and medical records. Treatment uptake was defined by: treatment initiation (the proportion initiating any kind of ART/HCV treatment when treatment-naïve) and coverage (the proportion ever treated for HIV/HCV) among all HIV-/HCV-RNA-positive PWUD. Each was calculated per calendar year. We estimated the cumulative probability of ART uptake in the pre-cART (
ISSN:	0955-3959 1873-4758
DOI:	10.1016/j.drugpo.2017.05.026